Listen

Press releases

Receive e-mail alerts

Internal link ProQR to Present at the JMP Securities Life Sciences Conference
June 03, 2019 at 11:00 AM UTC
Internal link ProQR to Present at the RBC Capital Markets Healthcare Conference
May 15, 2019 at 11:00 AM UTC
Internal link ProQR Announces Financial Results for the First Quarter of 2019
May 08, 2019 at 11:00 AM UTC
Internal link ProQR to Present at Three Scientific Conferences in April
April 22, 2019 at 11:00 AM UTC
Internal link ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board
April 18, 2019 at 11:00 AM UTC
Internal link ProQR Announces Annual Meeting of Shareholders
April 18, 2019 at 11:00 AM UTC
Internal link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
April 15, 2019 at 11:00 AM UTC
Internal link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference
April 01, 2019 at 11:00 AM UTC
Internal link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
March 26, 2019 at 08:01 PM UTC
Internal link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2
March 11, 2019 at 04:45 PM UTC
Internal link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
March 11, 2019 at 12:00 PM UTC
Internal link ProQR to Present at Cowen Health Care Conference
March 05, 2019 at 12:00 PM UTC
Internal link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
February 27, 2019 at 12:00 PM UTC
Internal link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
January 29, 2019 at 01:30 PM UTC
Internal link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
January 07, 2019 at 12:00 PM UTC
Internal link ProQR to Host R&D Day in New York on January 29
January 03, 2019 at 12:00 PM UTC
Internal link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
January 02, 2019 at 12:00 PM UTC
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index
December 24, 2018 at 12:00 PM UTC
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10
December 18, 2018 at 03:27 PM UTC
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10
December 17, 2018 at 04:52 PM UTC
Internal link ProQR Announces Strategic Changes to the Management Team and Key New Hires
December 13, 2018 at 12:00 PM UTC
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10
December 10, 2018 at 12:00 PM UTC
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
December 04, 2018 at 12:00 PM UTC
Internal link ProQR to Present at the Evercore ISI HealthConX Conference
November 20, 2018 at 12:00 PM UTC
Internal link ProQR Announces Financial Results for the Third Quarter of 2018
November 07, 2018 at 12:00 PM UTC

Press releases

Internal link ProQR to Present at the JMP Securities Life Sciences Conference

Internal link ProQR to Present at the RBC Capital Markets Healthcare Conference

Internal link ProQR Announces Financial Results for the First Quarter of 2019

Internal link ProQR to Present at Three Scientific Conferences in April

Internal link ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board

Internal link ProQR Announces Annual Meeting of Shareholders

Internal link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

Internal link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference

Internal link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership

Internal link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2

Internal link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

Internal link ProQR to Present at Cowen Health Care Conference

Internal link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

Internal link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day

Internal link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10

Internal link ProQR to Host R&D Day in New York on January 29

Internal link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index

Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10

Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10

Internal link ProQR Announces Strategic Changes to the Management Team and Key New Hires

Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10

Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients

Internal link ProQR to Present at the Evercore ISI HealthConX Conference

Internal link ProQR Announces Financial Results for the Third Quarter of 2018